Kiniksa Pharmaceuticals International, plc
KNSA
Peringkat dalam Saham
#2869
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Harga Saham
$81.52
Kapitalisasi Pasar
$6.36B
Perubahan (1 hari)
-1.98%
Perubahan (1 tahun)
109.83%
Negara
GB
Perdagangan Kiniksa Pharmaceuticals International, plc (KNSA)
Kategori
Healthcare
Pendapatan untuk Kiniksa Pharmaceuticals International, plc (KNSA)
Pendapatan pada Jun 2026 TTM: $840.85M
Menurut laporan keuangan terbaru dari Kiniksa Pharmaceuticals International, plc, pendapatan saat ini (TTM) adalah $840.85M. Pada tahun 2023, perusahaan menghasilkan pendapatan sebesar $270.26M peningkatan dibandingkan pendapatan pada tahun 2022 yang sebesar $220.18M. Pendapatan adalah jumlah total yang dihasilkan dari penjualan barang atau jasa. Tidak seperti laba, tidak ada pengeluaran yang dikurangkan.
Riwayat pendapatan Kiniksa Pharmaceuticals International, plc dari 2016 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Mengubah |
|---|---|---|
| 2026 (TTM) | $840.85M | 98.67% |
| 2024 | $423.24M | 56.60% |
| 2023 | $270.26M | 22.74% |
| 2022 | $220.18M | 471.24% |
| 2021 | $38.54M | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
Pendapatan untuk perusahaan serupa atau pesaing
| Perusahaan | Pendapatan | Perbedaan Pendapatan | Negara |
|---|---|---|---|
| $2.54B | 201.60% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| $830.81M | -1.19% |
US
|
|
| - | - |
IT
|
